# Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

> **NCT03358017** · PHASE2 · COMPLETED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 54 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Zoledronate
- **DRUG:** Atorvastatin 80mg
- **DRUG:** Standard neoadjuvant cht

## Key facts

- **NCT ID:** NCT03358017
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-05
- **Primary completion:** 2021-06-17
- **Final completion:** 2023-07-25
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03358017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03358017, "Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03358017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*